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This study attempted to determine if low density lipoproteins (LDL) induce the production of endothelins (ET) by human macrophagcs. 
Non-protected LDL from macrophage induced oxidation (n-LDL), copper-oxidized LDL (Ox-LDL). acetylated-LDL (AC-LDL). butylated 
hydroxytoluene-LDL (BHT-LDL). BHT-AC-LDL, polyinosinic acid (PiA, I .5 &ml). phorbol myristatc acetate (PMA; 0.5 PM) and BHT alone 
(20j1M) were studied. The different compoun& had the following potency to stimulate the ET secretion: PMABOx-LDLBAc-LDLBn-LDL>BHT- 
L.DLrPiA>PiA+Ac-LDL>BHT. In conclusioll, modified LDL stimulated ET secretion by human macrophagcs. 
Endothelin: Macrophage; Low density lipoprotein 
1. INTRODUCTION 
Low density lipoproteins (EDLs) are a well known 
atherogenic risk factor and may accumulate in vessel 
walls in hypercholesterolemia [1,2]. Recently. it has be- 
come evident that oxidatively modified LDLs (Ox- 
LDLs) contribute to the development of atherosclerosis 
[ 1,2]. The earliest recognized gross lesion in atherogene- 
sis is the fatty streak characterized by an accumulation 
of foam cells [ 1,2]. Ox-LDLs cause foam cell formation 
via the macrophage scavenger receptors [ 1.21. Macro- 
phages are a source of growth factors and cytokines [S] 
such as tumor necrosis factor (TNF) which can cause 
cell proliferation. Endothelin 1 (ET-l), a recently isolat- 
ed peptide secreted by endothelial cells, is a very potent 
vasoconstrictor [4] and presents a mitogenic activity on 
smooth-muscle cells and fibroblasts [5]. Therefore. ET 
may stimulate the formation of the atherosclerotic pla- 
ques. There is now evidence that Ox-LDLs induct the 
secretion of ET-l by endothelial cells [6] and that acetyl- 
ated-LDLs (AC-LDLs) induce the secretion cf TNF by 
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macrophages [7] via the scavenger receptors. On the 
other hand, it has been recently published that ET-l is 
produced by human macrophages stimulated with 
phorbol myristate acetate (PMA) [8]. On these grounds, 
we hypothesized that LDLs may trigger ET production 
by macrophages. Consequently, the goals of this study 
were (i) to determine if LDLs activate human macro- 
phages to secrete immunoreactive ET-l and ET-2 and 
(ii) to determine the eventual role of the macrophage 
scavenger receptors. 
2. MATERIALS AND METHODS 
Human LDL (n-LDL) (density 1.030-1.055 k@l) was isolated by 
scqucntial ultracentrifugation [9] from the blood of normolipidemic 
donors. Protein content was measured by Peterson’s method [I I]. 
LDLs were oxidized (Ox-LDL) by incubating EDTA-free n-LDL (0.1 
mg protein/ml) with CuSO, (5 PM) [I I] at 23°C. and acetylatcd-LDL 
(AC-LDL) was obtained with the repeated addition ofacctic anhydride 
according to Basu et al. [ 121. The dcgrcc of in vitro LDL oxidation was 
evaluated with three methods [ 131: (I) The increased itbsorption at 234 
nm. which indicates the increase in dicnc formation of fatty acids. The 
oxidation was stopped by the addition of EDTA when the OD incrcasc 
flattcncd; (2) The clcctrophoretic mobility on ccllulosc gel (Ccllogcl: 
Scbia, Issy-lcs moulincaux, France). The mean distance of migration 
was I35 + 18% in comparison with n-LDL, indiceting an cnhanccd 
ncgativc charge of Ox-LDL: (3) The TBARS assay, i.e. thiobarbituric 
acid rcactivc substances cxprcsscd as malonaldchydc (MDA) equiva- 
lcnts. The mean value was 5.2 ? 1.2 nM/ml. The non-lyophylyzed 
supcrnalant culture media wcrc conccntratcd and the dcgrcc of oxida- 
tion of lipoproteins was cvaluatcd according to method (2). Acctyla- 
tion of LDL was alsocontrollcd by this method. Butylated hydroxyto- 
lucnc (BHT). an antioxidant compound [I I]. was incorparalcd into 
lipoproteins prior to adding thcsc macromolcculcs into ccl1 culture 
medium. Briefly. 40 fig of BHT wcrc solubilizcd into IO ,uI of ethanol 
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Fig. 1. (A) Relative secretion of immunoreirrtive ET induced by differ- 
ent compounds. in comparison with the recretion induced by PMA 
(n=3: mean + SE). (B) Statistical comparison of the ET secretion in 
thedifferent groups using the Mann-Whitrey test; thedifferences were 
considered as significant when P<O.OS (‘ndicatcd by the shadowed 
area). 
and then added to 3 ml n-LDL or AC-LDL (I .6 mg protein/ml). This 
solution was gently mixed during 45 min and then dialyzed against a 
physiological salt solution gassed with 95% N?-5% CO:. BHT-lipo- 
proteins were sterilized by filtration (Milliporc: 0.22flM). An aliquot 
of this solution was used to evaluate the resistance of BHT-lipopro- 
teins against copper-induced oxidation. Following CuSO, (5 ,uM) 
addition into n-LDL and BHT-LDL solutions. the optical density 
(OD) was mcasurcd each hour for 6 h at 234 nm, and the time to reach 
the maximum OD was increased by 2 h in the presence of BHT. 
Monocytes wcrc obtained from healthy human donors. Blood mo- 
nonuclcar cells were sepdratcd on a lymphoprep discontinuous gra- 
dient 1101 and secdcd at a density of I5 x l0”/35-mm dish. They wcrc 
incubated in MEM supplemented with 10% (v/v) human serum of 
blood group Al3 rhesus-positive and monocytcs were allcwcd to attach 
for 2 h in S%I CO? at 37°C. At the end of the attachment period the 
medium was rcplaccd with MEM supplcmcntcd with IO% FCS for the 
rest of the cxperimcnts. Cells were used hc!wccn day 15 and 20 after 
seeding [8]. For each cxpcriment (rr=3). only cells dcrivcd from one 
donor were used. 
Before the assay, cells wcrc prc-incubated in growth medium con- 
taining 10% LPDS for 12 h. then incubated with cithcr MEM alone 
(ncgativc controls), or with PMA 0.5 PM (positive controls) or with 
diffcrcnt LDLs (l00~gIml mcdiun:): no;-p;z::ctcd LDL from macro- 
phagc induced oxidation (native-I.DL). n-LDL: copper-oxidized LDL 
(Ox-LDL). acctylatcd-LDL. (AC-LDL). butylatcd hydroxytolucnc (an 
antioxidant compound)-LDL (BHT-LDL) and BHT-AC-LDL. The 
effects of polyinosinic acid (PiA. 1.5 PJml). a competitor of AC-LDL 
for the scavcngcr receptors [ 141. and of BHT (20 PM) alone. wcrc also 
studied. After 20 h of incubation at 37°C. the medium was removed 
and cells washed twioc in phosphate buffcrcd saline. Supcrnatants 
wcrc conccntratcd for radioimmunoassays and cells wcrc rclcascd by 
addition of 5flOfllO. i N NaOH and proccsscd for protein dctcnnina- 
tion [I I], D~I:I arc rcprescntarivc of 3 preparations in triplicate. 
WC used Endothciin I ,2 (high sensitivity) [‘?“I]-RIA system (Amcr- 
sham. Lcs Ulis. France) to quantify immunorcactivc ET in the cultur- 
cd media. This R1A system offers ;I spccitic. scl:sitivc, rcliablc and 
prccisc qu;\ntir;ltivc dctcrrllilliltiol~ 01’ ET- I, ET-2 ;r~d Bip ET- I. ET- I 
can bc measured 
pg/tubc). 
in the range 0.25-3.2 fmol per tube (0.623-79.74 
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The ability of human macrophages to secrete ET,.1 
has been recently documented [8]. This publication has 
reported that PMA. which is a potent activator of PKC 
[ 161. could stimulate a 6- to 1 O-fold increase in the secre- 
tion of this peptide. In our study. we have found that 
the basal secretion (negative controls) of immunoreac- 
tive ET- l-2 was 177 -i- 44 fmol/mg cell proteins120 h and 
that PMA (positive control) stimulated secretion was 
822 -I- 45 fmol/mg cell proteins120 h (PcO.02. Mann- 
Whitney test). This increase is in agreement with the 
previously reported data [8]. Our results are presented 
in Fig. 1 as ‘relative secretion of immunoreactive ET-I- 
2. induced by lipoproteins’ in comparison with ‘secre- 
tion of immunoreactive ET-l-2 induced by PMA’. Th? 





[g;z:n: _ [ ~~!ZgI~::I) 
protcjn/20 h) 
induced by 
lipoproteins ET-‘-Z=loOx[~tion~ _ (ZYGiZ.&~~:) 
Our results show that Ox-LDL induced 100 + 27% of 
the ET-l-2 secretion induced by PMA and that n-LDL 
induced 45 + 2% of that secretion. On the basis of the 
previous report on the ability of human macrophagcs 
to produce ET [8] we chose a long incubation time for 
the lipoproteins with the cells (20 h). It has been exten- 
sively reported that such a long period of incubation 
induces LDL oxidation by macrophages [I .2], and it has 
been shown that BHT delays the cell-induced LDL oxi- 
dation [ 121. Therefore. in order to evaluate the potency 
of n-LDL. protected from macrophagic oxidation with 
BHT. on ET secretion we incubated BHT-LDLs with 
macrophages and WC observed that these protected 
LDLs induced 25 + 10% of the PMA-induced secretion. 
BHT alone did not modify ET secretion. After the 20 
h incubation wc studied. on ccllulosc gel. the elcctro- 
phorctic mobility of the lipoproteins contained in the 
culture media. Copper Ox-LDLs bade been further oxi- 
dized during the incubation period, as indicated by a 
faster mobility (Fig. 2A). Furthermore. in the incuba- 
tion media. most of the BHT-LDL had the same mobi- 
lity as n-LDL (Fig, 2B. lane 2 vs. tune 3), Thcrcforc, at 
the end time of t hc cxpcriments most c” the BHT-LDL 
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had been oxidized, although the intermediate band of 
the BHT-LDL (Fig. 2B, lane 2), located between native, 
fresh LDL (Fig. 2I3, lane 4) and the major bands of 
oxidized LDL of the culture medium (Fig. 2B, lanes 2 
and 3) was slightly lower than the intermediate band of 
the non-protected LDL (Fig. 2B. lane 3). This indicates 
that the oxidation of I_3HT-LDL was delayed. As we had 
verified that fresh BHT- LDLs were protected from cop- 
per-induced oxidation, we must state that this protec- 
tion was insufficient to ensure 20 h of macrophage- 
induced n-LDL oxidation. On the basis of that quoted 
in the literature [I21 and of the intermediate band seen 
in electrophoresis (Fig. 2B), we may suppose that BHT 
delayed the LDL oxidation and that the following phase 
of oxidation processing was accomplished before the 
end of the incubation period. Therefore, the duration of 
the contact between oxidized-LDLs and macrophages 
certainly increased as follows among the 3 groups of 
LDL: Ox-LDL > n-LDL > BHT-LDL. We remarked 
that this duration of contact follows the quantity of ET 
secreted by the macrophages (Fig. 1). It has been repor- 
ted that AC-LDLs induce the secretion of TNF, via the 
stimulation of the scavenger eceptors [7]. Therefore, we 
have formed the hypothesis that such receptors may be 
involved in modified LDL-induced ET secretion. Ac- 
LDLs and BHT-AC-LDLs induced 61 + 22% and 90 f 
43% of PMA-induced ET secretion, respectively. This 
secretion is higher than that induced by BHT-LDL, 
indicating that the scavenger receptors are probably 
invclved. We must note that the protection of the Ac- 
LDL oxidation by BHT did not reduce the ET secre- 
tion. After 20 h incubation AC-LDLs and BHT-Ac- 
LDLs of the media had the same mobility as fresh-AC- 
LDLs (Fig. 2C). This mobility was the same as that of 
LDL oxidized by macrophages (Fig. 2B) and did not 
allow an evaluation of the degree of oxidation of Ac- 
LDL and BHT-AC-LDL. In order to confirm the role 
of the scavenger receptors we chose to incubate the 
macrophages with polyinosinic acid (PiA), which is 
known to compete with AC-LDL for uptake and degra- 
dation by the scavenger macrophage receptors [ 151. PiA 
alone induced a moderate secretion of ET (20 C 15% of 
the PMA-induced secretion). in the presence of Pi& 
AC-LDLs induced II -t 5% of the PMA-induced secre- 
tion. Therefore, stimulation of the scavenger receptors’ 
pathway with a non-lipoprotein agonist can activate ET 
secretion. When PiA was bound to the receptors, the 
addition of Ac-LDL did not enhance ET secretion. This 
minimitcs the potency of lipid-lipid interactions be- 
twecn lipoproteins and cell membranes to induce the 
pcptide secretion, and confirms the importance of the 
scavenger receptors’ pathway in lipoprotein-induced 
ET sccrction, We must emphasize that Ox-LDLs arc 
more potent than AC-LDLs in inducing ET secretion. 
This is consistent with the reported data indicating that 
there is more than one macrophagc scavcngcr cccptor 
for modified LDL [ l7-191. Oxidizc&Y..vLs and Ac- 
Fig. 2. Elcctrophoretic mobility of LDLs. (A) lane I. fresh copper 
Ox-LDL; lane 2. copper Ox-LDL after 50 h incubation with macro- 
phages; lane 3. fresh n-LDL. (B) lane I. fresh BHT-LDL; lane 2. 
BHT-LDL after 20 h incubation with macrophagcs; lane 3. n-LDL 
after 20 h incubation with macrophagcs; lane 4. fresh n-LDL. (C) lane 
I. fresh AC-LDL; lane 2, BHT-AC-LDL after 20 h incubation with 
macrophagcs; lane 3. AC-LDL after 20 h incubation with macropha- 
ges; lane 4. fresh n-LDL. 
LDLs are not identical ligands with respect to macro- 
phage recognition and uptake. and there is a class of 
macrophage receptor that recognizes cell oxidized-i,DL 
but not AC-LDL [17]. This may partially explain the 
higher secretion of ET induced by Ox-LDL stimulation 
rather than by AC-LDL. The mechanism by which Ox- 
LDL and AC-LDL stimulate ET secretion via the scav- 
enger receptors is unknown. ET production in secreting 
cells is a complex process involving both transcriptional 
and post-transcriptional controls [20]. AC-LDL has 
recently been shown to be a general cellular activator 
which acts by increasing membrane receptor-mediated 
phosphatidylinositol turnover [21.22] which in turn se- 
condarily translocates PKC [23]. Thus, modified LDLs 
could act early in the sequence of activation, like 
phorbol ester tutnor promoters, which are potent acti- 
vators of PKC [ 161. 
Ox-LDLs and macrophages are involved in athero- 
genesis. Our study suggests one potentially important 
link between the two, through the secretion of ET. The 
role of ET in atherogenesis has not, however, been es- 
tablished. Nevertheless, its mitogenic action could faci- 
litate the transformation of fatty streaks into atheroma. 
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